| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.31 | 1e-08 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-08 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-07 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-06 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.28 | 2e-06 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.25 | 1e-05 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.24 | 3e-05 |